231 related articles for article (PubMed ID: 15589586)
1. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
[TBL] [Abstract][Full Text] [Related]
5. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
6. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
7. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M
Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
9. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
10. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
11. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients].
Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ
Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
13. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
14. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
15. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
16. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
17. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.
Murakami M; Gurski KJ; Marincola FM; Ackland J; Steller MA
Cancer Res; 1999 Mar; 59(6):1184-7. PubMed ID: 10096544
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
[TBL] [Abstract][Full Text] [Related]
20. [Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa].
Sima N; Wang W; Xu Q; Tian X; Luo AY; Lu YP; Wang SX; Ma D
Ai Zheng; 2007 Jan; 26(1):26-31. PubMed ID: 17222363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]